Beur schreef op 17 september 2018 12:26:
[...]Nog maar weer een keertje dan uit het CV van Dr.Jan de Kerpel van Kempen, door de Financial Times 3x verkozen tot beste biotechanalist van Europa:
R&D Director at Devgen N.V.
Invented and led the discovery, development and registration of the novel products. Tasks included daily management of nematicide business, strategy, IP, budgeting, M&A evaluations, ...
Participate in business development by means of evaluating global expansion opportunities, distribution negotiations, supply chain management, due dilligence.
Director of R&D team and chemical operations staff (~15 FTE, mainly MSc & PhD level)
Project leader in human therapeutics business (focus on different cardiovascular and metabolic diseases);
Initiation and implementation of enhanced R&D outsourcing (Europe, Asia);
Medicinal chemistry section leader, acting director of medicinal chemistry
Achievements: successful registration of two novel products, which entered the US and Asian markets. Obtained government research grant of >€ 3m. Created and lead a new business entity. Work resulted in several granted patents on new drug development candidates, currently further developed in a spin-off pharma company (Amakem)
Senior Scientist at Tibotec
Drug discovery and preclinical R&D of new HIV drugs, resulting in currently marketed products by JNJ (Prezista and Intelence);
Named inventor on several patents of new drugs and screening technologies;
Project leader for several discovery related projects;
Instrumental in enhancing the capacity and capability of the discovery unit (screening-chemistry-biology-preclinical);
Miscellaneous: research liaison contact between Tibotec USA and Tibotec NV (HQ, Belgium) and worked for Tibotec USA (Washington DC)
.
Maar goed, ook de meest deskundige op het gebied van biotech kan mis zitten. Zoals ik zelf ook denk dat hij nu mis zit met zijn koersdoel van 0,60